Visus Therapeutics Announces New Scientific Data to Be Presented at ARVO 2023
Visus Therapeutics announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held April 23-27, 2023 in New Orleans. The presentations will highlight new research findings on the company’s alpha-crystallin aggregation inhibitor assets. Alpha-crystallin aggregation inhibitors are intended to restore elasticity and lens clarity, potentially reversing presbyopia and cataracts without the need for surgery.
“We are pleased to share these scientific findings with the ophthalmic research community at ARVO 2023,” Rhett Schiffman, MD, MS, MHSA, co-founder, chief medical officer and head of research and development at Visus Therapeutics, said in a company news release. “Our non-clinical work investigates the use of alpha crystallin chaperones as aggregation inhibitors for the potential treatment of cataract, the leading cause of global blindness, and presbyopia, which affects nearly every adult over the age of 50. Exploring non-surgical therapeutic options to treat these diseases has the potential to improve the quality of life for millions of people around the world.”
The schedule of scientific presentations is as follows:
- Paper Title: Intravitreal α-Crystallin Chaperone Reverses Lens Opalescence in Non-Human Primates with Spontaneous Cataracts
- Date: Tuesday, April 25, 2023
- Time: 9:15am – 9:30am (Central Time)
- Location: 343
- Presenter: James Burke, Visus Therapeutics
- Poster Title: Next-Generation α-Crystallin Chaperones for the Treatment of Dysfunctional Lens Syndrome
- Date: Sunday, April 23, 2023
- Time: 3:45pm – 5:30pm (Central Time)
- Location: Exhibit Hall
- Presenter: Patrick Hughes, Visus Therapeutics